Trial Profile
KD-295 phase III study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs KD 295 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- 09 Jun 2016 New trial record